<DOC>
	<DOCNO>NCT02120729</DOCNO>
	<brief_summary>This Randomized Clinical Trial ( RCT ) compare outcomes 1500 patient major depressive disorder ( MDD ) treat accord patient 's CYP2D6 genotype status ( N=1000 ) versus empiric `` standard-of-care '' psychotropic therapy ( N=500 ) . The hypothesis provision medication base functional status patient 's CYP2D6 enzyme infer genotype result within 48 hour admission treat clinician , refine selection psychotropic medication hospitalization , decrease length psychiatric hospitalization stay decrease rate 30 day re-admission . The trial setting Hartford Hospital Institute Living ( IOL ) . The IOL operate Clinical Evaluation Monitoring System ( CEMS ) , innovative electronic messaging system develop Co-Investigator Dr. J.W . Goethe . The Hartford Hospital Genetics Research Center ( GRC ) perform genotype test . CYP2D6 genotype analysis detects know polymorphism result enzyme sub-normal supra-normal function . In study , CEMS transmit clinically actionable guidance base patient 's genotype clinician , advance medication alert real time . The RCT test effect timely incorporation medication recommendation base CYP2D6 genotype CEMS . The RCT assign 500 patient standard therapy ( Group S ) CYP2D6 genetic information determine transmit treat clinician , allow psychotropic therapy empirically determine , 1000 genetically guide therapy ( Group G ) genotyping result treatment recommendation furnish via CEMS clinician within 24 hour DNA sample 48 hour admission . For patient Group G poor rapid metabolizers , medication primarily metabolize CYP2D6 enzyme proscribed . The primary outcome hospital length stay secondary outcome , frequency 30 day hospital readmission . Additional genetic stratification Group S Group G allow investigation specific psychotropic usage . The expected benefit 1 ) quantitative understand effect provide CYP2D6 pharmacogenetic information length hospitalization , 30 day readmission rate , associate cost ; 2 ) objective benchmarking comparative effectiveness CYP2D6 genotyping guide psychotropic therapy .</brief_summary>
	<brief_title>Pharmacogenetic Decision Support IT System Psychiatric Hospitalization : RCT</brief_title>
	<detailed_description>Over 1.4 million hospitalization mental health condition occur annually United States ( 3.4 % hospitalization ) , half major depressive disorder ( MDD ) . Remarkably , 30 antidepressant antipsychotic medication available treat MDD , nearly 50 % primarily metabolize liver enzyme encode CYP2D6 gene . The CYP2D6 gene notable common sequence structural polymorphism markedly affect enzyme 's capacity , cause decrease increase drug metabolism 60 % patient , create challenge therapeutic management . The metabolic alteration cause CYP2D6 gene polymorphism may require long hospitalization due `` trial-and-error '' prescribing , delay improvement health status consumes resource . Reliable genotype test available detect array 19 gene alteration . Prescribing psychotropics use knowledge patient 's CYP2D6 gene status potentially cost effective . For research , Genetics Research Center perform CYP2D6 genotyping , Institute Living 's Clinical Evaluation Monitoring System ( CEMS ) transmit explicit alert regard prescription proscription specific psychotropics . The RCT compare outcomes patient whose treatment guide CYP2D6 functional status pharmacogenetic alert versus standard-of-care treatment test hypothesis provision clinically actionable prescription proscription information decrease hospitalization length stay reduce subsequent readmission . Using fund AHRQ R01 HS022304-01 , RCT enroll 1500 patient admit IOL next 5 year diagnosis MDD receive psychotropic therapy time admission receive psychotropic therapy hospitalization . 500 patient assign standard-of-care pharmacotherapy ( Group S ) , CYP2D6 genotype determine transmitted clinician psychotropic therapy follow institutional norm . 1000 patient assign genetically-guided pharmacotherapy ( Group G ) pharmacogenetic alert base CYP2D6 genotype furnish via CEMS clinician within 48 hour admission . Genotyping encompass 19 common polymorphism CYP2D6 quantification drug metabolism reserve index establish level sub-normal function ( poor metabolizer ) supra-normal function ( rapid metabolizer ) . For estimate 40 % patient Group G poor rapid metabolizers , CEMS proscribe medication major CYP2D6 substrate . The PI Dr. Gualberto Ruaño , Director GRC , lead clinician Co-I Dr. John Goethe , Director IOL 's Burlingame Research Center . Drs . Ruaño Goethe previously collaborate 8 year pharmacogenetics CYP450 psychotropics . Dr. Theodore Holford Yale University serve statistical consultant Dr. Richard Flockhart Indiana University serve medical consultant . The expected benefit quantitative understanding CYP2D6 pharmacogenetic information outcome associate cost psychiatric hospitalization . Importantly , Program provide objective benchmarking data comparative effectiveness CYP2D6 genotyping guide psychiatric inpatient prescription . The Specific Aims : 1 . RCT RECRUITMENT : To recruit 1500 patient Major Depressive Disorder admit IOL randomly assign 1000 Group G ( genetically guide ) 500 Group S ( standard care ) . 2 . RCT INTERVENTION : To conduct CYP2D6 genotyping null allele ( *3 , *4 , *4XN , *5 , *6 , *7 , *8 , *11 , *12 , *14 , *15 ) , deficient allele ( *9 , *10 , *17 , *41 ) , functional variant ( *1 , *2 ) , rapid allele ( *1XN , *2XN , *2a ) patient . In Group G genotyping result communicate treat clinician prescription proscription alert CYP2D6 substrate drug ; Group S , genotype withheld . 3 . PRIMARY ENDPOINT : To compare length hospitalization patient Groups G vs. S. 4 . SECONDARY ENDPOINT : To compare rate 30-day psychiatric hospital readmission Group G vs. S. 5 . ANCILLARY STUDIES : To assess impact genetic stratification Groups G vs. S. regard primary secondary endpoint specific drug utilization ( removal , addition , co-prescriptions ) .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>1 . Men woman age 18 old . 2 . Patients admit Institute Living diagnosis major depressive disorder 3 . The ability understand requirement study . 4 . The ability comply study procedure protocol . 5 . A woman eligible enter study childbearing potential pregnant nursing , childbearing potential . 1 . Children adolescents 2 . Hospital admission within previous 30 current admission . 3 . History dementia Alzheimer 's disease 4 . History chronic kidney disease ( CKD ) . 5 . Surgery within 6 wk . 6 . Ischemic stroke within 6 wk . 7 . Any history hemorrhagic stroke subarachnoid hemorrhage . 8 . Current enrollment investigational drug device study reach time primary end point</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pharmacogenetics</keyword>
	<keyword>CYP2D6 Mutations</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Psychiatric Inpatients</keyword>
	<keyword>Length Stay</keyword>
	<keyword>30 Day Readmission Rate</keyword>
	<keyword>Psychiatric hospital inpatient</keyword>
</DOC>